"Mitoxantrone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An anthracenedione-derived antineoplastic agent.
| Descriptor ID |
D008942
|
| MeSH Number(s) |
D02.455.426.559.847.117.159.500 D02.806.100.500 D04.615.117.159.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Mitoxantrone".
Below are MeSH descriptors whose meaning is more specific than "Mitoxantrone".
This graph shows the total number of publications written about "Mitoxantrone" by people in this website by year, and whether "Mitoxantrone" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 0 | 2 | 2 |
| 2018 | 2 | 2 | 4 |
| 2019 | 0 | 3 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Mitoxantrone" by people in Profiles.
-
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies. CNS Drugs. 2021 03; 35(3):317-330.
-
Molecular docking and simulation studies on SARS-CoV-2 Mpro reveals Mitoxantrone, Leucovorin, Birinapant, and Dynasore as potent drugs against COVID-19. J Biomol Struct Dyn. 2021 11; 39(18):7294-7305.
-
Discovery of Novel Inhibitors Targeting Human O-GlcNAcase: Docking-Based Virtual Screening, Biological Evaluation, Structural Modification, and Molecular Dynamics Simulation. J Chem Inf Model. 2019 10 28; 59(10):4374-4382.
-
Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study. J Clin Oncol. 2019 09 01; 37(25):2246-2256.
-
Identification and evaluation of antivirals for Rift Valley fever virus. Vet Microbiol. 2019 Mar; 230:110-116.
-
Elderly do benefit from induction chemotherapy: High dose mitoxantrone-based ("5 + 1") induction chemotherapy regimen in newly diagnosed acute myeloid leukemia. Am J Hematol. 2019 02; 94(2):209-215.
-
New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance. Leuk Lymphoma. 2019 03; 60(3):649-657.
-
In silico screening for ERa down modulators identifies thioridazine as an anti-proliferative agent in primary, 4OH-tamoxifen-resistant and Y537S ERa-expressing breast cancer cells. Cell Oncol (Dordr). 2018 Dec; 41(6):677-686.
-
Pregnancy planning and outcomes in patients with multiple sclerosis after mitoxantrone therapy: a monocentre assessment. Eur J Neurol. 2018 08; 25(8):1063-1068.
-
Durable response after VNCOP-B and rituximab in an elderly patient with high-grade B-cell lymphoma. Acta Clin Belg. 2018 Dec; 73(6):408-412.